Merck Abandons New Hepatitis C Drugs Amid Crowded Market
September 29 2017 - 9:33AM
Dow Jones News
By Cara Lombardo
Merck & Co. is halting development of new hepatitis C
treatments after reviewing their effectiveness and determining an
abundance of treatments, including its own drug, Zepatier, were
already available.
The market to treat the liver disease afflicting 3.5 million
Americans has become increasingly competitive, prompting Merck and
others to focus their attention elsewhere.
Johnson & Johnson's Janssen unit earlier this month
discontinued development of its own hepatitis C treatment, which
analysts said had good but not competitive results. The company
said it would focus on hepatitis B treatments, an area where there
are fewer options.
Merck, which made its decision after Phase 2 trials of two
combination regimens, said Friday it will study Zepatier in efforts
to bring it to more patients.
The FDA approved the use of Zepatier, a once-daily,
single-tablet combination of two drugs, grazoprevir and elbasvir,
to treat adults with two types of hepatitis C in 2016.
Merck shares, up 9.2% so far this year, were inactive in
premarket trading.
Merck recently recorded a $2.9 billion impairment charge related
to research and development of uprifosbuvir, the antiviral used in
the abandoned regimens, after lowering its value to $240 million
due to competition. Merck had acquired the drug-development program
through its purchase of Idenix Pharmaceuticals Inc. for $3.9
billion in 2014.
Gilead Sciences Inc., the market leader in hepatitis C, derived
40% of revenue in its latest quarter from hepatitis C treatments.
But those sales have been declining since 2015 as pricing pressures
increase.
AbbVie Inc. in August said it had received Food and Drug
Administration approval to sell its next-generation hepatitis C
treatment, Mavyret. The company said up to 95% of hepatitis C
patients will be eligible for the drug, which at $24,600 for a
standard course of treatment will cost less than older drugs from
AbbVie, Merck and Gilead.
Analysts at Leerink said Merck's announcement, combined with
J&J's plan, "changes everything" in terms of new treatments for
the virus.
"The commoditization of the category is likely to stop almost
immediately, and AbbVie and Gilead should establish some sort of
stable duopoly in this still massive disease indication," Leerink
said in a research note.
Gilead shares rose less than 1% premarket, while AbbVie shares
were little changed.
Write to Cara Lombardo at cara.lombardo@wsj.com
(END) Dow Jones Newswires
September 29, 2017 09:18 ET (13:18 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2023 to Apr 2024